Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
August 1, 12:35 PM
Bristol-Myers Squibb's (NYSE:BMY) short percent of float has fallen 29.89% since its last report. The company recently reported that it has 27.33 million shares sold short, which is 1.29% of all regular shares that are available for trading.
July 29, 5:24 PM
The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE…
July 28, 11:42 AM
According to Benzinga Pro, during Q2, Bristol-Myers Squibb (NYSE:BMY) earned $1.43 billion, a 11.38% increase from the preceding quarter. Bristol-Myers Squibb also posted a total of $11.89 billion in sales, a 2.05% increase since Q1.
Bristol-Myers Squibb Says In June, Transferred Commercial Ops In Russian Federation To Third-Party Distributor, Incurred $39M Of Exit Costs
July 27, 11:42 AM
July 27, 4:02 AM
With US stock futures trading higher this morning on Wednesday ahead of earnings reports from several big companies, some of the stocks that may grab investor focus today are as follows:
July 24, 4:37 PM
Big tech earnings will flow in thick and fast in the upcoming week, providing more clarity on how supply chain disruptions and the macroeconomic malaise have impacted these companies.
July 22, 5:59 PM
Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and…
July 19, 2:27 PM
Two companies in the psychedelics space have chosen new chief executive officers: COMPASS Pathways (NASDAQ: CMPS) has chosen Kabir Nath, and Small Pharma will be now led by George Tziras.